Страна: Ірландія
мова: англійська
Джерело: HPRA (Health Products Regulatory Authority)
RALOXIFENE HYDROCHLORIDE
Synthon BV
RALOXIFENE HYDROCHLORIDE
60 Milligram
Film Coated Tablet
Product subject to prescription which may be renewed (B)
Authorised
0000-00-00
M13.1_03.RXF.hcl.tab.001.03.IE.1551.03 PACKAGE LEAFLET : INFORMATION FOR THE USER Raloxiep 60 mg Film-coated Tablets (raloxifene hydrochloride) READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE. • Keep this leaflet. You may need to read it again. • If you have any further questions, ask your doctor or pharmacist. • This medicine has been prescribed for you. Do not pass it on to others. It may harm them, even if their symptoms are the same as yours. • If any of the side effects gets serious, or if you notice any side effects not listed in this leaflet, please tell your doctor or pharmacist. IN THIS LEAFLET: 1. What Raloxiep 60 mg Film-coated Tablets is and what it is used for 2. What you need to know before you take Raloxiep 60 mg Film-coated Tablets 3. How to take Raloxiep 60 mg Film-coated Tablets 4. Possible side effects 5. How to store Raloxiep 60 mg Film-coated Tablets 6. Contents of the pack and other information 1. WHAT RALOXIEP 60 MG FILM-COATED TABLETS IS AND WHAT IT IS USED FOR Raloxifene belongs to a group of non-hormonal medicines called Selective Estrogen Receptor Modulators (SERMs). When a woman reaches the menopause, the level of the female sex hormone oestrogen goes down. Raloxifene mimics the effects of oestrogen after the menopause. Raloxifene is used to treat and prevent osteoporosis in postmenopausal women. Raloxifene reduces the risk of fractures in the spine in women with postmenopausal osteoporosis. A reduction in the risk of hip fractures has not been shown. Osteoporosis is a disease Прочитайте повний документ
SUMMARY OF PRODUCT CHARACTERISTICS 1 NAME OF THE MEDICINAL PRODUCT Raloxiep 60 mg film-coated tablets 2 QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 60 mg raloxifene hydrochloride, equivalent to 56 mg raloxifene free base. Excipient with known effect: Each tablet contains 123.02 mg lactose monohydrate. For a full list of excipients, see section 6.1. 3 PHARMACEUTICAL FORM Film-coated tablet. White oval film-coated tablet, debossed with RX9F on one side and 60 on the other side. 4 CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS Raloxifene is indicated for the treatment and prevention of osteoporosis in postmenopausal women. A significant reduction in the incidence of vertebral, but not hip fractures has been demonstrated. When determining the choice of raloxifene or other therapies, including oestrogens, for an individual postmenopausal woman, consideration should be given to menopausal symptoms, effects on uterine and breast tissues, and cardiovascular risks and benefits (see Section 5.1). 4.2 POSOLOGY AND METHOD OF ADMINISTRATION Posology The recommended dose is one tablet daily by oral administration, which may be taken at any time of the day without regard to meals. Due to the nature of this disease process, raloxifene is intended for long term use. Generally calcium and vitamin D supplements are advised in women with a low dietary intake. _Elderly:_ No dose adjustment is necessary for the elderly. _Renal impairment_: Raloxifene should not be used in patients with severe renal impairment (see section 4.3). In patients with moderate and mild renal impairment, raloxifene should be used with caution. _Hepatic impairment:_ Raloxifene should not be used in patients with hepatic impairment (see section 4.3). 4.3 CONTRAINDICATIONS Hypersensitivity to the active substan Прочитайте повний документ